News

Immersive VR simulation helps patients better understand intraocular lens options.

Bausch + Lomb reveals promising results for the enVista Envy IOL, showcasing superior vision outcomes in cataract surgery patients.

Artificial intelligence is quickly expanding the breadth and depth of information clinicians can interpret, Prof Uy said

The virtual reality technology lets patients with cataract experience lens options in real-life scenarios, while a new strategic partnership aims to expand VR adoption.

At the EURETINA meeting, Professor Uy described the ways artificial intelligence can augment an existing imaging workflow.

OpZira’s product portfolio includes AdaptDx Pro and the NOVA Vision Testing System.

Wavelight plus was first launched in China, with several European and Asia-Pacific markets following suit

Findings from the retrospective, observational study support the potential anti-inflammatory benefits of the drug class.

At the ESCRS meeting, cataract surgeons can get familiar with BVI's Virtuoso platform and VirtuaLens' immersive VR IOL simulator

Alcon, Bausch + Lomb and Johnson & Johnson will debut new research findings during the European Society of Cataract and Refractive Surgeons Congress in Copenhagen, Denmark

From lids to retina, the 2-day event on September 26 and 27, 2025, at the Margaritaville Hollywood Beach Resort, Florida, offers a collaborative and comprehensive experience with actionable takeaways.

We ask leading experts in the field what eye disease they would cure and why.

The presence of AMD predicted an increased risk of all-cause and CVD mortality in patients with a high risk of CVD, even in the early stages of AMD.

Ahead of the ESCRS congress and iNovation day, we go behind the scenes with Ciliatech founder Philippe Sourdille, MD, and president Olivier Benoit

KOLs in the retina world reflect on advice they would share with fellows beginning their journey into retina, including the vast opportunities in healthcare and the importance of curiosity and collaboration for revolutionary advancements in retina medicine.

Sandoz received FDA approval for its biosimilar Enzeevu (aflibercept-abzv) on August 12, 2024. It has the same dosage form, route of administration, and presentation as the reference medicine, Eylea, from Regeneron.

This update from UHC includes procedures enabled with its OMNI Surgical System technology from Sight Sciences.

In both trials, Beacon’s lead program, laru-zova, was found to be well-tolerated by SKYLINE participants through month 36 and DAWN patients at month 9 or longer.

Roche reveals promising results for Vabysmo in treating eye diseases, showcasing significant vision improvements and safety in recent clinical trials.

The EURETINA YOURS program prepares retina specialists for the EBO exam and helps them find training in the competitive subspecialty of vitreoretinal surgery.

Beacon Therapeutics shares promising phase 2 trial results for laru-zova, a gene therapy showing potential in treating X-linked retinitis pigmentosa.

OCT-A angiography can help reveal early neurodegenerative disease signs, offering a non-invasive method for identifying high-risk patients through retinal analysis.

Prof Stanzel detailed new advancements in proliferative vitreoretinopathy and a hyperaspheric IOL designed for patients with age-related macular degeneration

Phentolamine ophthalmic solution 0.75% is for the treatment of significant, chronic night driving impairment in keratorefractive patients with reduced mesopic vision.